This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that Dr. James B. Wyngaarden has chosen to retire from the Company’s Board of Directors after 21 years of dedicated service. Dr Wyngaarden was a founding Board member of Idera and has served in various capacities, including Chairman of the Board.
“It has been my honor and pleasure to work with Jim for more than two decades,” said Sudhir Agrawal, D.Phil., Chairman and Chief Executive Officer of Idera. “Through his strategic leadership and deep knowledge of science and medicine, he has made immense contributions to Idera’s development for which we are deeply grateful. On behalf of Idera and its Board of Directors, I convey to Jim our most sincere thanks and best wishes.”
Dr. Wyngaarden joined the Company's board in 1990 and was appointed Vice Chairman in 1997. He served as Chairman of the Board from 2000 to 2010. Dr. Wyngaarden is Professor Emeritus at Duke University. At Duke, Dr. Wyngaarden served as Associate Vice Chancellor for Health Affairs, Chief of Staff and Physician-in-Chief at Duke University Hospital, and Frederic M. Hanes Professor and Chairman, Department of Medicine at the Duke University School of Medicine. From 1982 to 1989, Dr. Wyngaarden was Director, U.S. National Institutes of Health, and from 1989 to 1990 was Associate Director for Life Sciences, White House Office of Science and Technology Policy. Dr. Wyngaarden holds an M.D. (1948) from the University of Michigan Medical School. He is a member of the National Academy of Sciences (NAS) and the Institute of Medicine (IOM) and is a former Foreign Secretary of NAS and IOM.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals applies its proprietary Toll-like Receptor (TLR) drug discovery platform to create immunomodulatory drug candidates. The Company's TLR-targeted candidates are being developed to treat autoimmune and inflammatory diseases and cancer, and for use as vaccine adjuvants. Additionally, the Company is advancing its gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-promoting genes. For more information, visit